Key facts
- It has raised $1.3M; the latest was Early Stage VC ($1.1M) in May 2025.
- Notable investors include European Innovation Council, European Innovation Council (Belgium), Soulmates Ventures, Specialist VC, Superangel — 6 tracked in total.
- Better Medicine has filed 2 Form Ds with the SEC, most recently Apr 2018 ($850K sold to 7 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Better Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Better Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Better Medicine
Developer of an artificial intelligence-powered radiology platform designed to streamline cancer diagnostics and address inefficiencies in medical imaging workflows. The company's platform offers multi-organ analysis, automated lesion detection and measurement, integrated reporting tools, and compatibility with existing systems, enabling radiologists, oncology departments, and healthcare providers to improve diagnostic accuracy, reduce repetitive manual tasks, and deliver personalized care to cancer patients.
- Sector
- Healthcare
- HQ
- Tartu, Estonia
- Founded
- 2022
- Employees
- 9
- Website
- bettermedicine.ai/
- Ownership
- Privately Held (backing)
Better Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Better Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Better Medicine in its N-PORT filings yet. We sweep new filings monthly.